Insights


Updates in the Management of Myasthenia Gravis Insights

July 1st 2022

Expert neurologists review updates in the management of myasthenia gravis.

Multiple Sclerosis Care in Diverse Patient Populations: Challenges and Solutions

June 30th 2022

Experts in neurology share considerations for the management of ethnically diverse and underrepresented populations including those of reproductive age.

Recent Update on the Oral Management of Relapsing Remitting Multiple Sclerosis (MS)

June 29th 2022

Heidi Crayton, MD, provides an update on the oral management considerations in patients with relapsing remitting multiple sclerosis.

Updates in the Management of Myasthenia Gravis Peers and Perspectives

June 13th 2022

Expert neurologists review updates in the management of Myasthenia Gravis.

Optimizing Treatment of Relapsing-Remitting Multiple Sclerosis with Oral Therapies

April 20th 2022

Two multiple sclerosis experts discuss long-term and real-world data with oral therapies in the treatment of relapsing-remitting multiple sclerosis (RRMS) that was presented at ACTRIMS 2022.

Improving Diagnosis and Patient Outcomes in Narcolepsy

March 29th 2022

Experts in sleep medicine provide key insights on a series of patient cases and evaluate the use of novel agents in the treatment landscape for narcolepsy.

Practical Considerations in the Management of OFF-Episodes in Parkinson Disease

March 24th 2022

Expert neurologists examine strategies for optimizing treatment formulations in the management of OFF episodes in Parkinson disease and highlight the importance of patient education.

Management of Multiple Sclerosis in the Era of COVID-19 Pandemic

March 10th 2022

Klaus Schmierer, MB BS, PhD, FRCP, discusses how patients with multiple sclerosis have been impacted by the COVID-19 pandemic, including guideline recommendations regarding vaccinations.

Testing for Early Diagnosis of Alzheimer’s Disease

January 25th 2022

Alireza Atri, MD, PhD, discusses the many methods of testing and forming a diagnosis for patients with Alzheimer’s disease, highlighting the recent FDA approval of aducanumab and its impact.

Advances in the Testing and Treatment of Alzheimer’s Disease

December 23rd 2021

Jeffrey L. Cummings, MD, ScD, discusses the Alzheimer’s disease and the advances recently made to improve the treatment landscape, specifically with aducanumab.